Luo D, et al. - Researchers analyzed 854 studies with 4,345 patients in order to examine the link between the hypoxia-inducible factor-2α (HIF2α) status and clinical outcome in human cancer. Via electronic databases, they screened studies online. Using available publications, they calculated pooled risk ratios or hazard ratios with their 95% confidence intervals. In both univariate analysis and multivariate analysis, unfavorable overall survival could be predicted by increased expression of HIF2α in cancer patients. Moreover, a close relation of HIF2α overexpression to tumor differentiation, tumor–node–metastasis stage, and lymph metastasis was evident. Overall, they concluded a possible role of HIF2α as a marker of poor prognosis and clinicopathologic characteristics of tumors. HIF2α could be a new biomarker in human cancer.